Clinical Trial

Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.
Protocol Amendment History 5 changes
critical Trial status changed: RECRUITING → ACTIVE_NOT_RECRUITING 2026-07-21
notable Primary completion pushed: 2026-10-07 -> 2026-11-18 2026-07-02
minor Completion pushed: 2026-10-07 -> 2026-11-18 2026-07-02
critical Recruitment opened 2026-04-28
notable Trial sites expanded: 0 -> 3 locations 2026-04-28
Trial Details
NCT Number NCT07523711
Lead Sponsor Amgen
Conditions Overweight, Obesity
Enrollment 49 participants
Start Date 2026-04-09
Primary Completion 2026-11-18 (estimated)
Study Completion 2026-11-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-20